Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy, safety, and tolerability of GRT6005 in subjects with moderate to severe chronic low back pain
2012-001920-36Phase 2Completed
- Sponsor
- Grünenthal GmbH
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cebranopadol in chronic low back pain (CLBP), lumbodynia (LBP), sponsored by Grünenthal GmbH. Started Aug 2012; status: completed.
02
Drugs
cebranopadol
03
Conditions
chronic low back pain (CLBP)lumbodynia (LBP)
Beyond the preview
Go deeper on 2012-001920-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001920-36.